

Cover Story
Real-world Evidence
By Matthew Bin Han Ong
Routine screening procedures for breast, colon, and cervical cancers in the first half of 2021 have failed to recover, falling by about a third below historical baselines, even as Americans are resuming normal activities.
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- California Institute of Regenerative Medicine and Cancer Research: A promise broken?
- GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation
- Two lawsuits vs. Tempus raise questions about privacy of germline data in cancer RWE
“Deidentified” ≠ “deidentifiable” - Bernie Lewinsky’s collection of artifacts captures “the learning curve” of radiation oncology
- Sustaining community oncology through nonprofit structures and shared technology infrastructure















